

Christian Hartinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2301430/publications.pdf>

Version: 2024-02-01

243
papers

17,375
citations

11608

70
h-index

16127

124
g-index

265
all docs

265
docs citations

265
times ranked

10336
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of the ferrocenyl group on cytotoxicity and KSP inhibitory activity of ferrocenyl monastrol conjugates. Dalton Transactions, 2022, 51, 491-508.	1.6	6
2	Heterotrimetallic Double Cavity Cages: Syntheses and Selective Guest Binding. Angewandte Chemie, 2022, 134, .	1.6	10
3	Heterotrimetallic Double Cavity Cages: Syntheses and Selective Guest Binding. Angewandte Chemie - International Edition, 2022, 61, e202201700.	7.2	35
4	Substitution of the chlorido ligand for PPh ₃ in anticancer organoruthenium complexes of sulfonamide-functionalized pyridine-2-carbothioamides leads to high cytotoxic activity. Inorganica Chimica Acta, 2022, 536, 120889.	1.2	7
5	Tracing the anticancer compound [Ru ^{II} (⁶ -p-cymene)(8-oxyquinolato)Cl] in a biological environment by mass spectrometric methods. Analytical Methods, 2021, 13, 1463-1469.	1.3	6
6	High Antiproliferative Activity of Hydroxythiopyridones over Hydroxypyridones and Their Organoruthenium Complexes. Biomedicines, 2021, 9, 123.	1.4	8
7	Impact of the Metal Center and Leaving Group on the Anticancer Activity of Organometallic Complexes of Pyridine-2-carbothioamide. Molecules, 2021, 26, 833.	1.7	11
8	Homodinuclear organometallics of ditopic N,N-chelates: Synthesis, reactivity and in vitro anticancer activity. Inorganica Chimica Acta, 2021, 518, 120220.	1.2	4
9	Biological properties of ruthenium(II)/(III) complexes with flavonoids as ligands. Coordination Chemistry Reviews, 2021, 436, 213849.	9.5	37
10	Carbon monoxide is an inhibitor of HIF prolyl hydroxylase domain 2. ChemBioChem, 2021, 22, 2521-2525.	1.3	3
11	Heptadentate, Octadentate, Or Even Nonadentate? Denticity in the Unexpected Formation of an All-Carbon Donor-Atom Ligand in Rh ^{III} (Cp*)(Anthracenyl-NHC) Complexes. Inorganic Chemistry, 2021, 60, 8734-8741.	1.9	7
12	Dinuclear orthometallated gold(I)-gold(III) anticancer complexes with potent <i>in vivo</i> activity through an ROS-dependent mechanism. Metallomics, 2021, 13, .	1.0	6
13	Cavity-Containing [Fe ₂ L ₃] ⁴⁺ Helicates: An Examination of Host-Guest Chemistry and Cytotoxicity. Frontiers in Chemistry, 2021, 9, 697684.	1.8	2
14	Probing the Paradigm of Promiscuity for N-Heterocyclic Carbene Complexes and their Protein Adduct Formation. Angewandte Chemie, 2021, 133, 20081-20085.	1.6	1
15	Triazolyl-Functionalized N-Heterocyclic Carbene Half-Sandwich Compounds: Coordination Mode, Reactivity and <i>in vitro</i> Anticancer Activity. ChemMedChem, 2021, 16, 3017-3026.	1.6	7
16	Monodentately-coordinated bioactive moieties in multimodal half-sandwich organoruthenium anticancer agents. Coordination Chemistry Reviews, 2021, 439, 213890.	9.5	44
17	Probing the Paradigm of Promiscuity for N-Heterocyclic Carbene Complexes and their Protein Adduct Formation. Angewandte Chemie - International Edition, 2021, 60, 19928-19932.	7.2	24
18	Anthracenyl Functionalization of Half-Sandwich Carbene Complexes: In Vitro Anticancer Activity and Reactions with Biomolecules. Inorganic Chemistry, 2021, 60, 14636-14644.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Determination of Relative Stabilities of Metal–Peptide Bonds in the Gas Phase. <i>Chemistry - A European Journal</i> , 2021, 27, 16401-16406.	1.7	1
20	Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands. <i>Coordination Chemistry Reviews</i> , 2021, 445, 213950.	9.5	45
21	In-flow SAXS investigation of whey protein isolate hydrolyzed by bromelain. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2021, 631, 127662.	2.3	5
22	Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells. <i>Pharmaceuticals</i> , 2021, 14, 103.	1.7	10
23	Mustards-Derived Terpyridine–Platinum Complexes as Anticancer Agents: DNA Alkylation vs Coordination. <i>Inorganic Chemistry</i> , 2021, 60, 2414-2424.	1.9	26
24	Incorporation of α -Alanine in Cu(II) ATCUN Peptide Complexes Increases ROS Levels, DNA Cleavage and Antiproliferative Activity**. <i>Chemistry - A European Journal</i> , 2021, 27, 18093-18102.	1.7	12
25	Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Pharmaceuticals</i> , 2021, 14, 1020.	1.7	6
26	Synthetic Strategy Towards Heterodimetallic Half-Sandwich Complexes Based on a Symmetric Ditopic Ligand. <i>Frontiers in Chemistry</i> , 2021, 9, 786367.	1.8	3
27	A Solid Support–Based Synthetic Strategy for the Site–Selective Functionalization of Peptides with Organometallic Half–Sandwich Moieties. <i>Chemistry - A European Journal</i> , 2021, , .	1.7	3
28	From the hypothesis-driven development of organometallic anticancer drugs to new methods in mode of action studies. <i>Advances in Inorganic Chemistry</i> , 2020, 75, 339-359.	0.4	4
29	Metalloproteomics for molecular target identification of protein-binding anticancer metallodrugs. <i>Metallomics</i> , 2020, 12, 1627-1636.	1.0	23
30	Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands. <i>Inorganic Chemistry</i> , 2020, 59, 14879-14890.	1.9	11
31	A Combined Spectroscopic and Protein Crystallography Study Reveals Protein Interactions of Rh ^I (NHC) Complexes at the Molecular Level. <i>Inorganic Chemistry</i> , 2020, 59, 17191-17199.	1.9	14
32	Thiourea-Derived Chelating Ligands and Their Organometallic Compounds: Investigations into Their Anticancer Activity. <i>Molecules</i> , 2020, 25, 3661.	1.7	9
33	A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 14609-14614.	7.2	22
34	A Reduced–Symmetry Heterobimetallic [PdPtL ₄] ⁴⁺ Cage: Assembly, Guest Binding, and Stimulus–Induced Switching. <i>Angewandte Chemie</i> , 2020, 132, 11194-11200.	1.6	29
35	A Reduced–Symmetry Heterobimetallic [PdPtL ₄] ⁴⁺ Cage: Assembly, Guest Binding, and Stimulus–Induced Switching. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 11101-11107.	7.2	89
36	Potent Inhibition of Thioredoxin Reductase by the Rh Derivatives of Anticancer M(arene/Cp*)(NHC)Cl ₂ Complexes. <i>Inorganic Chemistry</i> , 2020, 59, 3281-3289.	1.9	53

#	ARTICLE	IF	CITATIONS
37	A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. <i>Angewandte Chemie</i> , 2020, 132, 14717-14722.	1.6	4
38	Hydroxyquinoline-derived anticancer organometallics: Introduction of amphiphilic PTA as an ancillary ligand increases their aqueous solubility. <i>Journal of Inorganic Biochemistry</i> , 2019, 199, 110768.	1.5	33
39	Anticancer organorhodium and -iridium complexes with low toxicity <i>in vivo</i> but high potency <i>in vitro</i> : DNA damage, reactive oxygen species formation, and haemolytic activity. <i>Chemical Communications</i> , 2019, 55, 12016-12019.	2.2	40
40	Coordination Chemistry of Organoruthenium Compounds with Benzoylthiourea Ligands and their Biological Properties. <i>Chemistry - an Asian Journal</i> , 2019, 14, 1262-1270.	1.7	25
41	Gel electrophoresis in combination with laser ablation-inductively coupled plasma mass spectrometry to quantify the interaction of cisplatin with human serum albumin. <i>Electrophoresis</i> , 2019, 40, 2329-2335.	1.3	6
42	Comparative solution studies and cytotoxicity of gallium(III) and iron(III) complexes of 3-hydroxy-2(1H)-pyridinones. <i>Polyhedron</i> , 2019, 172, 141-147.	1.0	3
43	Design of organoruthenium complexes for nanoparticle functionalization. <i>Journal of Organometallic Chemistry</i> , 2019, 891, 64-71.	0.8	0
44	<i>Medicinal Chemistry</i> , 2019, , 157-172.		4
45	Chemical imaging and assessment of cadmium distribution in the human body. <i>Metallomics</i> , 2019, 11, 2010-2019.	1.0	58
46	Structural Modifications of the Antiinflammatory Oxicam Scaffold and Preparation of Anticancer Organometallic Compounds. <i>Organometallics</i> , 2019, 38, 361-374.	1.1	27
47	Metallomic study on the metabolism of RAPTA-C and cisplatin in cell culture medium and its impact on cell accumulation. <i>Metallomics</i> , 2018, 10, 455-462.	1.0	21
48	Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein-Ru(carbene) adduct. <i>Chemical Communications</i> , 2018, 54, 6120-6123.	2.2	34
49	13. ANTITUMOR METALLODRUGS THAT TARGET PROTEINS. , 2018, 18, 351-386.		13
50	Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. <i>Inorganic Chemistry</i> , 2018, 57, 2851-2864.	1.9	45
51	13. Antitumor Metallodrugs that Target Proteins. , 2018, 18, 351-386.		7
52	Anticancer metallodrugs: where is the next cisplatin?. <i>Future Medicinal Chemistry</i> , 2018, 10, 615-617.	1.1	128
53	Analysis of ruthenium anticancer agents by MEEKC-UV and MEEKC-ICP-MS: Impact of structural motifs on lipophilicity and biological activity. <i>Electrophoresis</i> , 2018, 39, 1201-1207.	1.3	15
54	Quinoline- <i>para</i> -quinones and metals: coordination-assisted formation of quinoline- <i>ortho</i> -quinones. <i>Chemical Communications</i> , 2018, 54, 992-995.	2.2	13

#	ARTICLE	IF	CITATIONS
55	Making organoruthenium complexes of 8-hydroxyquinolines more hydrophilic: impact of a novel <i>l</i> -phenylalanine-derived arene ligand on the biological activity. Dalton Transactions, 2018, 47, 2192-2201.	1.6	31
56	Advanced metallomics methods in anticancer metallodrug mode of action studies. TrAC - Trends in Analytical Chemistry, 2018, 104, 110-117.	5.8	19
57	Structure-activity relationships for ruthenium and osmium anticancer agents towards clinical development. Chemical Society Reviews, 2018, 47, 909-928.	18.7	330
58	Organometallics in Cancer Treatment-Non-conventional Structures and Modes of Action. , 2018, , .		0
59	From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived <i>N</i> -Heterocyclic-Carbene Complexes as Anticancer Agents. Inorganic Chemistry, 2018, 57, 14427-14434.	1.9	54
60	Hybrid compounds from chalcone and 1,2-benzothiazine pharmacophores as selective inhibitors of alkaline phosphatase isozymes. European Journal of Medicinal Chemistry, 2018, 159, 282-291.	2.6	16
61	Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC-ICP-MS. Monatshefte für Chemie, 2018, 149, 1719-1726.	0.9	22
62	Organoruthenium and Organoosmium Complexes of π -Pyridinecarbothioamides Functionalized with a Sulfonamide Motif: Synthesis, Cytotoxicity and Biomolecule Interactions. ChemPlusChem, 2018, 83, 612-619.	1.3	12
63	Hyphenation of capillary electrophoresis to inductively coupled plasma mass spectrometry with a modified coaxial sheath-flow interface. Journal of Chromatography A, 2018, 1561, 76-82.	1.8	7
64	A Bioactive <i>l</i> -Phenylalanine-Derived Arene in Multitargeted Organoruthenium Compounds: Impact on the Antiproliferative Activity and Mode of Action. Inorganic Chemistry, 2018, 57, 8521-8529.	1.9	26
65	Understanding the interactions of diruthenium anticancer agents with amino acids. Journal of Biological Inorganic Chemistry, 2018, 23, 1159-1164.	1.1	13
66	(Pyridin-2-yl)-NHC Organoruthenium Complexes: Antiproliferative Properties and Reactivity toward Biomolecules. Organometallics, 2018, 37, 1575-1584.	1.1	35
67	Cobalt complexes as internal standards for capillary zone electrophoresis-mass spectrometry studies in biological inorganic chemistry. Journal of Biological Inorganic Chemistry, 2017, 22, 789-798.	1.1	4
68	Aspirin-inspired organometallic compounds: Structural characterization and cytotoxicity. Journal of Organometallic Chemistry, 2017, 839, 31-37.	0.8	23
69	Anti-inflammatory Oxicams as Multi-donor Ligand Systems: η^5 - and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os. Chemistry - A European Journal, 2017, 23, 4893-4902.	1.7	33
70	An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. Angewandte Chemie - International Edition, 2017, 56, 8267-8271.	7.2	97
71	Functionalization of Ruthenium(II)(η^6 - <i>p</i> -cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies. ChemPlusChem, 2017, 82, 841-847.	1.3	13
72	The metalation of hen egg white lysozyme impacts protein stability as shown by ion mobility mass spectrometry, differential scanning calorimetry, and X-ray crystallography. Chemical Communications, 2017, 53, 4246-4249.	2.2	34

#	ARTICLE	IF	CITATIONS
73	Synthesis and in vitro Biological Evaluation of Ferrocenyl Side-Chain-Functionalized Paclitaxel Derivatives. <i>ChemMedChem</i> , 2017, 12, 1882-1892.	1.6	17
74	Anticancer Ru(η -6-p-cymene) complexes of 2-pyridinecarbothioamides: A structure-activity relationship study. <i>Journal of Inorganic Biochemistry</i> , 2017, 177, 395-401.	1.5	28
75	Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay. <i>Journal of Inorganic Biochemistry</i> , 2017, 177, 322-327.	1.5	35
76	Innenrücktitelbild: Ein Organoruthenium-Tumorthapeutikum mit unerwartet hoher Selektivität für Plectin (<i>Angew. Chem.</i> 28/2017). <i>Angewandte Chemie</i> , 2017, 129, 8415-8415.	1.6	0
77	Ein Organoruthenium-Tumorthapeutikum mit unerwartet hoher Selektivität für Plectin. <i>Angewandte Chemie</i> , 2017, 129, 8379-8383.	1.6	14
78	AsBIC8 - 8th Asia/Pacific Biological Inorganic Chemistry Conference. <i>Journal of Inorganic Biochemistry</i> , 2017, 177, 248.	1.5	0
79	8th Asian Biological Inorganic Chemistry Conference. <i>Journal of Biological Inorganic Chemistry</i> , 2017, 22, 637-638.	1.1	0
80	DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metallodrug binding selectivity. <i>Chemical Communications</i> , 2017, 53, 8002-8005.	2.2	26
81	Cationic Ru(η -6-p-cymene) Complexes of 3-Hydroxy-4-pyr(id)ones - Lipophilic Triphenylphosphine as Co-Ligand Is Key to Highly Stable and Cytotoxic Anticancer Agents. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1721-1727.	1.0	27
82	Reprint of: Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies. <i>Inorganica Chimica Acta</i> , 2017, 454, 247-253.	1.2	2
83	The Analysis of Therapeutic Metal Complexes and Their Biomolecular Interactions. , 2017, , 355-386.		0
84	Ru(η -6-p-cymene) Complexes of Bioactive 1,2-Benzothiazines: Protein Binding vs. Antitumor Activity. <i>European Journal of Inorganic Chemistry</i> , 2016, 2016, 1376-1382.	1.0	26
85	Electrophoretic separation techniques and their hyphenation to mass spectrometry in biological inorganic chemistry. <i>Electrophoresis</i> , 2016, 37, 959-972.	1.3	23
86	Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies. <i>Inorganica Chimica Acta</i> , 2016, 450, 124-130.	1.2	14
87	Towards targeting anticancer drugs: ruthenium(η -arene) complexes with biologically active naphthoquinone-derived ligand systems. <i>Dalton Transactions</i> , 2016, 45, 13091-13103.	1.6	45
88	Ferrocenyl Paclitaxel and Docetaxel Derivatives: Impact of an Organometallic Moiety on the Mode of Action of Taxanes. <i>Chemistry - A European Journal</i> , 2016, 22, 11413-11421.	1.7	25
89	Flavonoid-Based Organometallics with Different Metal Centers - Investigations of the Effects on Reactivity and Cytotoxicity. <i>European Journal of Inorganic Chemistry</i> , 2016, 2016, 240-246.	1.0	21
90	Anticancer activity of Ru- and Os(arene) compounds of a maleimide-functionalized bioactive pyridinecarbothioamide ligand. <i>Journal of Inorganic Biochemistry</i> , 2016, 165, 100-107.	1.5	38

#	ARTICLE	IF	CITATIONS
91	Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 250-255.	1.5	94
92	Metal complexes of benzimidazole derived sulfonamide: Synthesis, molecular structures and antimicrobial activity. <i>Inorganica Chimica Acta</i> , 2016, 443, 179-185.	1.2	49
93	The development of RAPTA compounds for the treatment of tumors. <i>Coordination Chemistry Reviews</i> , 2016, 306, 86-114.	9.5	375
94	N-(4-Benzoylphenyl)pyridine-2-carbothioamide. <i>IUCrData</i> , 2016, 1, .	0.1	0
95	Expanding on the Structural Diversity of Flavone- Derived Ruthenium(II)-arene Anticancer Agents. <i>MetalloDrugs</i> , 2015, 1, .	1.7	15
96	Organoruthenium and Osmium Anticancer Complexes Bearing a Maleimide Functional Group: Reactivity to Cysteine, Stability, and Cytotoxicity. <i>ChemPlusChem</i> , 2015, 80, 231-236.	1.3	31
97	Physicochemical studies on the copper(II) binding by glycosylated collagen telopeptides. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 3058-3063.	1.5	12
98	Half-Sandwich Ruthenium(II) Biotin Conjugates as Biological Vectors to Cancer Cells. <i>Chemistry - A European Journal</i> , 2015, 21, 5110-5117.	1.7	60
99	Extravasation of Pt-based chemotherapeutics – bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS). <i>Metallomics</i> , 2015, 7, 508-515.	1.0	27
100	Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action. <i>Chemical Science</i> , 2015, 6, 2449-2456.	3.7	127
101	Capillary electrophoresis in metallodrug development. <i>Drug Discovery Today: Technologies</i> , 2015, 16, 16-22.	4.0	9
102	The rearrangement of tosylated flavones to 1-(alkylamino)aurones with primary amines. <i>Tetrahedron</i> , 2015, 71, 8953-8959.	1.0	12
103	Impact of the Halogen Substitution Pattern on the Biological Activity of Organoruthenium 8-Hydroxyquinoline Anticancer Agents. <i>Organometallics</i> , 2015, 34, 5658-5668.	1.1	133
104	Protein ruthenation and DNA alkylation: chlorambucil-functionalized RAPTA complexes and their anticancer activity. <i>Dalton Transactions</i> , 2015, 44, 3614-3623.	1.6	68
105	Solution equilibrium studies of anticancer ruthenium(II)-p-cymene complexes of pyridinecarboxylic acids. <i>Polyhedron</i> , 2014, 67, 51-58.	1.0	13
106	Efficiently Detecting Metallodrug-Protein Adducts: Ion Trap versus Time-of-Flight Mass Analyzers. <i>ChemMedChem</i> , 2014, 9, 1351-1355.	1.6	11
107	Opening the lid on piano-stool complexes: An account of Ruthenium(II)-arene complexes with medicinal applications. <i>Journal of Organometallic Chemistry</i> , 2014, 751, 251-260.	0.8	236
108	Anticancer Ruthenium(II)-p-cymene Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives. <i>Organometallics</i> , 2014, 33, 5546-5553.	1.1	82

#	ARTICLE	IF	CITATIONS
109	Development of anticancer agents: wizardry with osmium. <i>Drug Discovery Today</i> , 2014, 19, 1640-1648.	3.2	139
110	Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: Synthesis, solution speciation and bioactivity. <i>Journal of Inorganic Biochemistry</i> , 2014, 134, 57-65.	1.5	73
111	Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. <i>Dalton Transactions</i> , 2014, 43, 9851.	1.6	7
112	Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. <i>Metallomics</i> , 2014, 6, 1616-1625.	1.0	58
113	Ruthenium(II)(η -6-arene) Complexes of Thiourea Derivatives: Synthesis, Characterization and Urease Inhibition. <i>Molecules</i> , 2014, 19, 8080-8092.	1.7	27
114	A systematic capillary electrophoresis study on the effect of the buffer composition on the reactivity of the anticancer drug cisplatin to the DNA model 2'-deoxyguanosine 5'-monophosphate (dGMP). <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 6417-6424.	1.9	14
115	Anticancer metallodrug research analytically painting the "omics picture" current developments and future trends. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 1791-1808.	1.9	57
116	Solution equilibria of anticancer ruthenium(II)-(η -6-p-cymene)-hydroxy(thio)pyr(id)one complexes: Impact of sulfur vs. oxygen donor systems on the speciation and bioactivity. <i>Journal of Inorganic Biochemistry</i> , 2013, 127, 161-168.	1.5	24
117	Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2013, 18, 249-260.	1.1	16
118	Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies. <i>Journal of Biological Inorganic Chemistry</i> , 2013, 18, 9-17.	1.1	125
119	Rhodium(Cp*) Compounds with Flavone-derived Ligand Systems: Synthesis and Characterization. <i>Zeitschrift Fur Anorganische Und Allgemeine Chemie</i> , 2013, 639, 1648-1654.	0.6	17
120	Identification of the Structural Determinants for Anticancer Activity of a Ruthenium Arene Peptide Conjugate. <i>Chemistry - A European Journal</i> , 2013, 19, 9297-9307.	1.7	58
121	A new target for gold(I) compounds: Glutathione-S-transferase inhibition by auranofin. <i>Journal of Inorganic Biochemistry</i> , 2013, 119, 38-42.	1.5	39
122	Novel metal(II) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents. <i>Chemical Science</i> , 2013, 4, 1837.	3.7	111
123	Solution equilibrium studies on anticancer ruthenium(II)- η -6-p-cymene complexes of 3-hydroxy-2(1H)-pyridones. <i>Journal of Organometallic Chemistry</i> , 2013, 734, 38-44.	0.8	20
124	DNA damaging properties of single walled carbon nanotubes in human colon carcinoma cells. <i>Nanotoxicology</i> , 2013, 7, 2-20.	1.6	23
125	3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands. <i>Dalton Transactions</i> , 2013, 42, 6193-6202.	1.6	74
126	Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. <i>Chemical Society Reviews</i> , 2013, 42, 6186.	18.7	132

#	ARTICLE	IF	CITATIONS
127	Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. <i>Chemical Communications</i> , 2013, 49, 3348.	2.2	127
128	Am(m)ines Make the Difference: Organoruthenium Am(m)ine Complexes and Their Chemistry in Anticancer Drug Development. <i>Chemistry - A European Journal</i> , 2013, 19, 4308-4318.	1.7	31
129	Influence of the π -coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes. <i>Frontiers in Chemistry</i> , 2013, 1, 27.	1.8	23
130	Capillary zone electrophoresis and capillary zone electrophoresis- μ electrospray ionization mass spectrometry studies on the behavior of anticancer cis- and trans-[dihalidobis(2-propanone) Tj ETQq0 0 0 rgBT /Overback 10 Tf50 617 T		
131	Challenges and Opportunities in the Development of Organometallic Anticancer Drugs. <i>Organometallics</i> , 2012, 31, 5677-5685.	1.1	507
132	Organometallic Ruthenium and Osmium Compounds of Pyridin α 2 α and α 4 α ones as Potential Anticancer Agents. <i>Chemistry and Biodiversity</i> , 2012, 9, 1718-1727.	1.0	17
133	Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder. <i>Chemical Communications</i> , 2012, 48, 4839.	2.2	130
134	Comparative solution equilibrium studies of anticancer gallium(III) complexes of 8-hydroxyquinoline and hydroxy(thio)pyrone ligands. <i>Journal of Inorganic Biochemistry</i> , 2012, 117, 189-197.	1.5	53
135	Synthesis and Biological Evaluation of the Thionated Antibacterial Agent Nalidixic Acid and Its Organoruthenium(II) Complex. <i>Organometallics</i> , 2012, 31, 5867-5874.	1.1	62
136	Structure-Activity Relationships of Targeted Ru ^{II} (η -6-Cymene) Anticancer Complexes with Flavonol-Derived Ligands. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10512-10522.	2.9	132
137	Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs. <i>Molecular Pharmacology</i> , 2012, 81, 719-728.	1.0	54
138	Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules. <i>Chemical Communications</i> , 2012, 48, 1475-1477.	2.2	91
139	Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: New methodology and applications. <i>Electrophoresis</i> , 2012, 33, 622-634.	1.3	22
140	Anthracene-Tethered Ruthenium(II) Arene Complexes as Tools To Visualize the Cellular Localization of Putative Organometallic Anticancer Compounds. <i>Inorganic Chemistry</i> , 2012, 51, 3633-3639.	1.9	54
141	Synthesis of [RuII(η -6-p-cymene)(PPh ₃)(L)Cl]PF ₆ complexes with carbohydrate-derived phosphites, imidazole or indazole co-ligands. <i>Inorganica Chimica Acta</i> , 2012, 380, 211-215.	1.2	10
142	Biomolecule binding vs. anticancer activity: Reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins. <i>Journal of Inorganic Biochemistry</i> , 2012, 108, 91-95.	1.5	53
143	Fragmentation methods on the balance: unambiguous top-down mass spectrometric characterization of oxaliplatin-ubiquitin binding sites. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 2655-2662.	1.9	39
144	Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. <i>Journal of Biological Inorganic Chemistry</i> , 2012, 17, 465-474.	1.1	51

#	ARTICLE	IF	CITATIONS
145	Physicochemical Studies and Anticancer Potency of Ruthenium π -Cymene Complexes Containing Antibacterial Quinolones. <i>Organometallics</i> , 2011, 30, 2506-2512.	1.1	105
146	LC and CZE ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma. <i>Metallomics</i> , 2011, 3, 1049.	1.0	62
147	Anticancer Activity of Metal Complexes: Involvement of Redox Processes. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 1085-1127.	2.5	420
148	Platinum nanoparticles and their cellular uptake and DNA platination at non-cytotoxic concentrations. <i>Archives of Toxicology</i> , 2011, 85, 799-812.	1.9	125
149	A Ruthenium Antimetastasis Agent Forms Specific Histone Protein Adducts in the Nucleosome Core. <i>Chemistry - A European Journal</i> , 2011, 17, 3562-3566.	1.7	160
150	Interactions of the carrier ligands of antidiabetic metal complexes with human serum albumin: A combined spectroscopic and separation approach with molecular modeling studies. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 4202-4210.	1.4	23
151	Pyrone derivatives and metals: From natural products to metal-based drugs. <i>Journal of Organometallic Chemistry</i> , 2011, 696, 999-1010.	0.8	86
152	Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 46-51.	1.5	107
153	From hydrolytically labile to hydrolytically stable Ru π -arene anticancer complexes with carbohydrate-derived co-ligands. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 224-231.	1.5	65
154	Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2688-2702.	1.0	80
155	Editorial [Hot Topic: Metal Containing Complexes with Anticancer Properties (Guest Editors: A.)] <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 1-10.	1.0	10
156	Osmium(II) versus ruthenium(II) π -arene carbohydrate-based anticancer compounds: similarities and differences. <i>Dalton Transactions</i> , 2010, 39, 7345.	1.6	88
157	Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry. <i>Journal of Biological Inorganic Chemistry</i> , 2010, 15, 677-688.	1.1	86
158	Metabolization of [Ru(π -6-C ₆ H ₅ CF ₃)(pta)Cl ₂]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand. <i>Journal of Biological Inorganic Chemistry</i> , 2010, 15, 919-927.	1.1	45
159	Synthesis, Cytotoxicity, and COMPARE Analysis of Ferrocene and [3]Ferrocenophane Tetrasubstituted Olefin Derivatives against Human Cancer Cells. <i>ChemMedChem</i> , 2010, 5, 2039-2050.	1.6	76
160	The first example of MEEKC-ICP-MS coupling and its application for the analysis of anticancer platinum complexes. <i>Electrophoresis</i> , 2010, 31, 1144-1150.	1.3	45
161	An Internal Fluorescent Probe Based on Anthracene to Evaluate Cation-Anion Interactions in Imidazolium Salts. <i>Chemistry - A European Journal</i> , 2010, 16, 6473-6481.	1.7	21
162	Trapping Unstable Benzoquinone Analogues by Coordination to a [(π -5-C ₅ Me ₅)Ir] Fragment and the Anticancer Activity of the Resulting Complexes. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 8304-8305.	7.2	16

#	ARTICLE	IF	CITATIONS
163	Mannich products of kojic acid and N-heterocycles and their Ru(II) η^6 -arene complexes: Synthesis, characterization and stability. <i>Journal of Organometallic Chemistry</i> , 2010, 695, 875-881.	0.8	26
164	Synthesis and characterisation of the water soluble bis-phosphine complex [Ru(η^6 -cymene)(PPh ₂ (<i>o</i> -C ₆ H ₄ O)- η^2 -P,O)(pta)] ⁺ and an investigation of its cytotoxic effects. <i>Comptes Rendus Chimie</i> , 2010, 13, 1144-1150.	0.2	14
165	Organometallic Antitumour Agents with Alternative Modes of Action. <i>Topics in Organometallic Chemistry</i> , 2010, , 57-80.	0.7	57
166	Is the Reactivity of M(II) η^6 -Arene Complexes of 3-Hydroxy-2(1 <i>H</i>)-pyridones to Biomolecules the Anticancer Activity Determining Parameter?. <i>Inorganic Chemistry</i> , 2010, 49, 7953-7963.	1.9	101
167	{(1 <i>R</i> ,2 <i>R</i> ,4 <i>R</i>)-4-Methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): A Novel Enantiomerically Pure Oxaliplatin Derivative Showing Improved Anticancer Activity in Vivo. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7356-7364.	2.9	51
168	Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol Ruthenium(II) η^6 -(η^6 -Arene) Complexes. <i>Australian Journal of Chemistry</i> , 2010, 63, 1521.	0.5	33
169	Nitrile-functionalized pyrrolidinium ionic liquids as solvents for cross-coupling reactions involving in situ generated nanoparticlecatalyst reservoirs. <i>Physical Chemistry Chemical Physics</i> , 2010, 12, 1834-1841.	1.3	58
170	DNA interactions of dinuclear Ru(II) arene antitumor complexes in cell-free media. <i>Biochemical Pharmacology</i> , 2009, 77, 364-374.	2.0	76
171	Maltol-Derived Ruthenium η^6 -Cymene Complexes with Tumor Inhibiting Properties: The Impact of Ligand-Metal Bond Stability on Anticancer Activity In Vitro. <i>Chemistry - A European Journal</i> , 2009, 15, 12283-12291.	1.7	111
172	New Insights into the Chemistry of the Antineoplastic Lanthanum Complex Tris(1,10-phenanthroline)tris(thiocyanato)lanthanum(III) (KP772) and Its Interaction with Biomolecules. <i>European Journal of Inorganic Chemistry</i> , 2009, 2009, 4282-4287.	1.0	33
173	The serum protein binding of pharmacologically active gallium(III) compounds assessed by hyphenated CE-MS techniques. <i>Electrophoresis</i> , 2009, 30, 2720-2727.	1.3	48
174	Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro protein binding studies by means of CE-ICP-MS. <i>Electrophoresis</i> , 2009, 30, 4075-4082.	1.3	24
175	Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety. <i>Journal of Organometallic Chemistry</i> , 2009, 694, 922-929.	0.8	64
176	A one step/one pot synthesis of N,N-bis(phosphonomethyl)amino acids and their effects on adipogenic and osteogenic differentiation of human mesenchymal stem cells. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 3388-3393.	1.4	10
177	Bioorganometallic chemistry—from teaching paradigms to medicinal applications. <i>Chemical Society Reviews</i> , 2009, 38, 391-401.	18.7	916
178	Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta. <i>Organometallics</i> , 2009, 28, 1165-1172.	1.1	79
179	Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 916-925.	2.9	168
180	From Pyrone to Thiopyrone Ligands—Rendering Maltol-Derived Ruthenium(II) η^6 -Arene Complexes That Are Anticancer Active in Vitro. <i>Organometallics</i> , 2009, 28, 4249-4251.	1.1	85

#	ARTICLE	IF	CITATIONS
181	Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on the <i>In Vitro</i> Antitumor Activity of Polynuclear Organometallic Compounds. <i>Organometallics</i> , 2009, 28, 6260-6265.	1.1	92
182	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. <i>Journal of Analytical Atomic Spectrometry</i> , 2009, 24, 51-61.	1.6	100
183	Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. <i>Anti-Cancer Drugs</i> , 2009, 20, 97-103.	0.7	214
184	5-Hydroxy-2-methyl-4H-pyran-4-one. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2009, 65, o437-o437.	0.2	2
185	Linked Metal-cluster Systems: Isolation and Characterisation of {anti-[(p-cymene)RuCl] _{1/4} -[P ₂ P ₂] ₁ -P ₂ -(PPh ₂ CH ₂) ₃ CMe]-[AuPt ₃ (CO) ₃ (PCy ₃) ₃]}(PF ₆) ₂ . <i>Journal of Cluster Science</i> , 2008, 19, 295-309.	1.7	5
186	The ruthenium(II) arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53/JNK pathways. <i>Journal of Biological Inorganic Chemistry</i> , 2008, 13, 1149-1155.	1.1	232
187	In Vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrate-Based Ligands. <i>Chemistry - A European Journal</i> , 2008, 14, 9046-9057.	1.7	111
188	Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: A novel approach for the analysis of anticancer metallodrugs in human serum and plasma. <i>Electrophoresis</i> , 2008, 29, 2224-2232.	1.3	86
189	Elucidation of the Interactions of an Anticancer Ruthenium Complex in Clinical Trials with Biomolecules Utilizing Capillary Electrophoresis Hyphenated to Inductively Coupled Plasma-Mass Spectrometry. <i>Short Communication. Chemistry and Biodiversity</i> , 2008, 5, 1609-1614.	1.0	33
190	Phosphite-Derivatized Ruthenium-Carbohydrate Complexes in the Catalytic Hydration of Nitriles. <i>Short Communication. Chemistry and Biodiversity</i> , 2008, 5, 1640-1644.	1.0	22
191	The Hydration of Chloroacetonitriles Catalyzed by Mono- and Dinuclear Ru ^{II} and Os ^{II} -Arene Complexes. <i>Chemistry and Biodiversity</i> , 2008, 5, 2060-2066.	1.0	21
192	KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. <i>Chemistry and Biodiversity</i> , 2008, 5, 2140-2155.	1.0	732
193	Modifying the structure of dinuclear ruthenium complexes with antitumor activity. <i>Applied Organometallic Chemistry</i> , 2008, 22, 326-332.	1.7	45
194	Studies on the reactivity of organometallic Ru, Rh and Os-pta complexes with DNA model compounds. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 1066-1076.	1.5	101
195	Gold(III) compounds as anticancer agents: Relevance of gold-protein interactions for their mechanism of action. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 564-575.	1.5	249
196	CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 1060-1065.	1.5	92
197	Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(η ⁶ -p-cymene)Cl ₂ (pta)]. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 1743-1748.	1.5	108
198	Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: Relevance to antitumour activity. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 2136-2141.	1.5	59

#	ARTICLE	IF	CITATIONS
199	Methyl-substituted trans-1,2-cyclohexanediamines as new ligands for oxaliplatin-type complexes. <i>Tetrahedron</i> , 2008, 64, 137-146.	1.0	10
200	Emerging Protein Targets for Anticancer Metallo drugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium(II)-Arene Compounds. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6773-6781.	2.9	258
201	Resistance against novel anticancer metal compounds: Differences and similarities. <i>Drug Resistance Updates</i> , 2008, 11, 1-16.	6.5	201
202	Characterization of Platinum Anticancer Drug Protein-Binding Sites Using a Top-Down Mass Spectrometric Approach. <i>Inorganic Chemistry</i> , 2008, 47, 17-19.	1.9	91
203	Influence of the Spacer Length on the <i>in Vitro</i> Anticancer Activity of Dinuclear Ruthenium-Arene Compounds. <i>Organometallics</i> , 2008, 27, 2405-2407.	1.1	180
204	Suzuki Coupling Reactions in Ether-Functionalized Ionic Liquids: The Importance of Weakly Interacting Cations. <i>Organometallics</i> , 2008, 27, 3971-3977.	1.1	78
205	High Resolution Mass Spectrometry for Studying the Interactions of Cisplatin with Oligonucleotides. <i>Inorganic Chemistry</i> , 2008, 47, 10626-10633.	1.9	63
206	Carbohydrate-Metal Complexes and their Potential as Anticancer Agents. <i>Current Medicinal Chemistry</i> , 2008, 15, 2574-2591.	1.2	160
207	Reversion of Structure-Activity Relationships of Antitumor Platinum Complexes by Acetoxime but Not Hydroxylamine Ligands. <i>Molecular Pharmacology</i> , 2007, 71, 357-365.	1.0	53
208	Mass spectrometric analysis of ubiquitin-platinum interactions of leading anticancer drugs: MALDI versus ESI. <i>Journal of Analytical Atomic Spectrometry</i> , 2007, 22, 960-967.	1.6	89
209	Tuning the hydrophobicity of ruthenium(ii)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. <i>Dalton Transactions</i> , 2007, , 5065.	1.6	131
210	Structure-Activity Relationships for NAMI-A-type Complexes (HL)[trans-RuCl ₄ L(S-dmsoruthenate(III)] (L = Imidazole, Indazole, 1,2,4-Triazole, 4-Amino-1,2,4-triazole, and 1-Methyl-1,2,4-triazole): Aquation, Redox Properties, Protein Binding, and Antiproliferative Activity. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 2185-2193.	2.9	206
211	Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE. <i>Electrophoresis</i> , 2007, 28, 2235-2240.	1.3	46
212	CE in anticancer metallo drug research – an update. <i>Electrophoresis</i> , 2007, 28, 3436-3446.	1.3	59
213	A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?. <i>ChemMedChem</i> , 2007, 2, 505-514.	1.6	49
214	Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis. <i>Journal of Chromatography A</i> , 2007, 1155, 218-221.	1.8	33
215	Antitumour metal compounds: more than theme and variations. <i>Dalton Transactions</i> , 2007, , 183-194.	1.6	767
216	Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. <i>Dalton Transactions</i> , 2006, , 1796.	1.6	197

#	ARTICLE	IF	CITATIONS
217	DNA Interactions of pH-Sensitive, Antitumor Bis(aminoalcohol)dichloroplatinum(II) Complexes. <i>Biochemistry</i> , 2006, 45, 14817-14825.	1.2	27
218	Interactions of Antitumor Metallodrugs with Serum Proteins: Advances in Characterization Using Modern Analytical Methodology. <i>Chemical Reviews</i> , 2006, 106, 2224-2248.	23.0	570
219	Electrospray ionization mass spectrometric study on the coordination behavior of dacarbazine towards transition metal ions. <i>Polyhedron</i> , 2006, 25, 1971-1978.	1.0	6
220	From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 891-904.	1.5	882
221	Metallodrug research and analysis using capillary electrophoresis. <i>TrAC - Trends in Analytical Chemistry</i> , 2006, 25, 868-875.	5.8	46
222	Platinum group metallodrug-protein binding studies by capillary electrophoresis – inductively coupled plasma-mass spectrometry: A further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins. <i>Electrophoresis</i> , 2006, 27, 1128-1135.	1.3	100
223	Glucose ferrocenyl-oxazolines: Coordination behavior toward [Pd(η -3-allyl)Cl] ₂ studied by ESI-MS. <i>Journal of Organometallic Chemistry</i> , 2005, 690, 3301-3308.	0.8	16
224	Bis- and tris-bicycloposphites of d-glucofuranoside. Unexpected catalysis of P(III/V)-oxidation by triethylamine. <i>Tetrahedron</i> , 2005, 61, 10943-10950.	1.0	6
225	Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis. <i>Analytical Biochemistry</i> , 2005, 341, 326-333.	1.1	85
226	1,1'-Bis(oxazolin-2-yl)ferrocenes: An Investigation of Their Complexation Behavior toward [Pd(η -3-allyl)Cl] ₂ . <i>European Journal of Inorganic Chemistry</i> , 2005, 2005, 1589-1600.	1.0	14
227	Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method. <i>Journal of Separation Science</i> , 2005, 28, 121-127.	1.3	80
228	On the Coordination Properties of New Bicycloposphite-Carbohydrates. <i>Monatshefte für Chemie</i> , 2005, 136, 137-146.	0.9	2
229	Tumour-inhibiting platinum(ii) complexes with aminoalcohol ligands: biologically important transformations studied by micellar electrokinetic chromatography, nuclear magnetic resonance spectroscopy and mass spectrometry. <i>Analyst</i> , 2005, 130, 1383.	1.7	23
230	Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(iii) compound with plasma proteins. <i>Journal of Analytical Atomic Spectrometry</i> , 2005, 20, 856.	1.6	99
231	Redox-Active Antineoplastic Ruthenium Complexes with Indazole: Correlation of in Vitro Potency and Reduction Potential. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2831-2837.	2.9	156
232	Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: Characterization of interactions between Pt(II) complexes and human serum albumin. <i>Electrophoresis</i> , 2004, 25, 1988-1995.	1.3	125
233	Analysis of Platinum Adducts with DNA Nucleotides and Nucleosides by Capillary Electrophoresis Coupled to ESI-MS: Indications of Guanosine 5'-Monophosphate O6-N7 Chelation. <i>ChemBioChem</i> , 2004, 5, 1543-1549.	1.3	52
234	Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato- η^2 N,O)platinum(II) – a representative of novel pH sensitive anticancer platinum complexes. <i>Inorganica Chimica Acta</i> , 2004, 357, 3237-3244.	1.2	46

#	ARTICLE	IF	CITATIONS
235	A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl ₄ (Ind) ₂] and serum proteins. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 1135-1142.	1.5	79
236	Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. <i>Journal of Analytical Atomic Spectrometry</i> , 2004, 19, 46.	1.6	183
237	Capillary electrophoresis in anti-cancer metallodrug research: Advances and future challenges. <i>Electrophoresis</i> , 2003, 24, 2023-2037.	1.3	55
238	Tumor-inhibiting platinum(II) complexes with aminoalcohol ligands: Comparison of the mode of action by capillary electrophoresis and electrospray ionization-mass spectrometry. <i>Electrophoresis</i> , 2003, 24, 2038-2044.	1.3	37
239	Crystallographic report: Crystal structure of 1-bromo-1'-[(2S)-N-(1-hydroxy-3-methylbutane-2-yl)]-ferroceneamide. <i>Applied Organometallic Chemistry</i> , 2003, 17, 723-724.	1.7	0
240	Synthesis, crystal structures, and electrospray ionisation mass spectrometry investigations of ether- and thioether-substituted ferrocenes. <i>Dalton Transactions</i> , 2003, , 3098.	1.6	8
241	Novel glucose-ferrocenyl derivatives: synthesis and properties. <i>New Journal of Chemistry</i> , 2002, 26, 671-673.	1.4	28
242	Synthesis of ferrocenylglucose phosphonite and bisphosphinite: Pd(II) and Pt(II) complexes, Pd-catalyzed allylic alkylation. <i>Tetrahedron</i> , 2002, 58, 8489-8492.	1.0	23
243	1,1,3,3-Tetramethyl-1,3-disila-2-oxa[3]ferrocenophane: improved synthesis and new crystal structure. <i>Inorganica Chimica Acta</i> , 2002, 328, 237-240.	1.2	7